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1. Introduction 
The term colitis describes variety of inflammatory diseases of the colon which can be 
differentiated according to their etiology, clinical, endoscopic and histological 
characteristics. In general, they can be classified as inflammatory bowel diseases (IBD) and 
infectious colitis (Hemstreet & Diprio, 2008; Novaneethan & Giannella, 2011), and non-IBD 
and non-infectious colitis, including ischemic colitis, chemical colitis, microscopic colitis, 
segmental colitis, radiation colitis, diversion colitis, eosinophilic colitis and Behcet’s colitis 
(Koutroubakis, 2008). The two forms of idiopathic IBD, ulcerative colitis (UC), a mucosal 
inflammatory condition restricted to the rectum and colon, and Crohn’s disease (CD), a 
transmural inflammation of the GIT affecting any part from the mouth to anus, are the most 
prevalent, especially in the western countries and in areas of northern latitude. Other forms, 
such as diversion colitis, eosinophilic colitis and Behcet’s colitis are rare, with unknown 
ethiopathogenesis and limited epidemiological data. Clinical presentation of all forms is 
very similar and includes mild, moderate or severe local complications, such as diarrhea, 
abdominal pain or cramping, rectal bleeding and weight loss, and systemic ones, including 
hepatobiliary, joint, ocular, renal, dermatologic and mucosal complications.  
The goals of the treatment include resolving of the acute inflammation and associated 
complications, alleviation of the systemic manifestations and maintenance of remission. Besides 
non-pharmacologic therapy, which includes nutritional support and surgical intervention, 
pharmacologic therapy is an integral part of the overall treatment of colitis. All the drugs are 
aimed to control the disease allowing the patient to perform normal daily activities. The main 
pharmacologic groups of drugs used for colitis treatment include aminosalycilates, 
corticosteroids, immunosuppressive agents, antimicrobials and inhibitors of TNF-┙.  
In addition, for maintaining remission in various GI diseases, including colitis, live bacterial 
cell biotherapeutics i.e probiotics, alone or combined with prebiotics as synbiotics, are also 
administered. Probiotics are defined as “viable microorganisms which alter the microflora (by 
implantation or colonization) in a compartment of the host and by that exert beneficial effects 
in the host”, while prebiotics as “non-digestible food ingredients that beneficially affect the 
host by selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon” are considered (Gibson & Roberfroid, 1995). For prevention and 
maintaining of remission in colitis, various probiotics were clinically examined during the last 
decade, among which non-pathogenic E. coli, strains of bifidobacteria, lactobacilli, Streptococcus 
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thermophilus, enterococci, coliforms, Bacteroides and Clostridium perfringens. From the prebiotics, 
the commercially available fructooligosaccharides (FOS), inulin and galactooligosaccharides 
are frequently used and many other potential prebiotics are still under investigation, among 
which xylooligosaccharides, soy-oligosacharides, pesticooligosaccharides, 
glucooligosaccharides, isomaltooligosaccharides and gentiooligosaccharides (Table 1). 
 
Probiotic strain Therapeutic effect References 
B. bifidium, B. breve, B. 
infantis, B. lactis LA 303, B. 
longum infantis UCC35624, B. 
longum, L. acidophilus LA 201, 
L. acidophilus, L. casei Shirota, 
L. casei subsp. Rhamnosus, L. 
delbruecki subsp. Bulgaricus, L. 
fermentum BR11, L. plantarum 
299V, L. plantarum LA 301, L. 
paracasei, L. reuteri, L. 
rhamnosus GG, L. salivarius 
LA 302, L. salivarius UCC118, 
Lactococcus lactis, non-
pathogenic E. coli Nisle 1917, 
Sacharomyces boulardi, Str. 
boulardi, Str. salivarius subsp. 
Thermophilus 
Maintain balance of beneficial vs. 
aggressive commensal enteric 
microflora: inhibit pathogenic enteric 
bacteria (decrease luminal pH, secrete 
bactericidal proteins, resist colonization, 
block epithelial binding-induction of 
MUC2, inhibit epithelial invasion–Rho 
(in)dependent pathways); improve 
function of epithelial and mucosal 
barrier (produce short chain fatty acids 
(SCFAs), enhance mucus production, 
increase barrier integrity); alter immune-
regulation (induce IL-10 and 
transforming growth factor ┚ expression 
and secretion, stimulate secretory IgA 
production, decrease tumor necrosis 
factor expression).  
Geier et al., 2007; 
Peran et al., 2007; 
Prakash, 2008. 
Prebiotic   
Inulin, lactulose, goat’s milk 
oligosacaccharides, fructo-
oligosaccharide, hemi-
celluloses- and glutamine- 
rich extract, maltodextrin 
Decrease level of the pro-inflammatory 
cytokine IL-1┚, increase anti-
inflammatory TGF-┚, increase caecal 
lactobacillus and bifidobacterium levels, 
decrease E. coli colonization, decrease 
clostridium and enterobacterium levels, 
increase levels of SCFAs.   
Geier et al., 2007; 
Gibson & 
Roberfroid, 1995. 
Table 1. Health benefits of different probiotic strains and prebiotics in colitis 
Considering the pharmacologic treatment, many patients experience significant undesired 
effects (Table 2) which require discontinuation of the therapy. Avoiding or minimizing these 
effects is one of the great challenges in the pharmaceutical industry in which great effort is 
put on design of an ideal drug delivery system that would deliver the drug at a rate dictated 
by the needs of the patient within the period of treatment and target it to the specific i.e. 
inflamed site of the colon. Considering probiotics, the greatest achievement with these 
advanced delivery systems is their potential to protect the probiotics not only in the pro- or 
syn-biotic food or pharmaceutical product, but also from the harsh environment of the GIT, 
and to maintain their functionality unaltered on arrival to the colon. All these prerequisites 
require modified drug and/or cell release technologies which can improve the therapeutic 
efficacy and safety by precise temporal and spatial placement in the colon, thereby reducing 
both the dose and the frequency of administration. 
www.intechopen.com
 
Drug and Cell Delivery Systems in the Treatment of Colitis 
 
133 
 
Drug Adverse effects References 
Aminosalycilates 
Sulfasalazine 
Mesalamine  
(5-Aminosalicylic 
acid; 5-ASA) 
Agranulocytosis, pancreatitis, interstitial nephritis, 
hepatitis, male infertility, arthralgia, pneumonitis. 
Mesalazaine derivatives manifest lower frequency 
of adverse effects in comparison with sulfasalazine. 
Hemstreet & Diprio, 
2008; Linares et al., 
2011; Sonu al., 2010.  
Corticosteroids 
Budesonide 
Prednisone 
Prednisolone 
Dexamethasone 
Hyperglycemia, hypertension, electrolyte 
disturbances, cataracts, osteoporosis, myopathy, 
conditions associated with immune suppression, 
adrenal insufficiency (long-term administration). 
Ford et al., 2011. 
Imunosupressive agents 
Azathioprine 
 
 
Methotrexate 
 
 
Cyclosporine 
Pancreatitis, fever, rash, arthralgia, diarrhea, 
infectious complications, hepatitis, myelo-
suppression, known carcinogen. 
Diarrhea, skin reactions, bone marrow suppression, 
lung lesions, kidney dysfunction, hepatotoxicity, 
folic acid deficiency. 
Paresthesias, hypertension, nephrotoxicity, seizures.
Gisbert et al., 2009; 
Hemstreet & Diprio, 
2008; Wahed et al., 2009. 
Antimicrobial agents 
Metronidazole 
 
Vancomycin 
 
 
 
 
Ciprofloxacin 
 
 
 
Tobramycin 
Urticaria, glossitis; long-term use may develop 
paresthesia, reversible peripheral neuropathy. 
Infusion related events, nephrotoxicity, pseudo-
membranous colitis, ototoxicity, reversible 
neutropenia, infrequently anaphylaxis, eosinophilia, 
rashes including exfoliative dermatitis, linear IgA 
bullous dermatosis, Steven-Johnson syndrome, 
vasculitis. 
Diarrhea, vomiting and rash. Other side effects (e.g. 
headache, abdominal pain, pain in extremities, 
injection site reaction, cardiovascular, 
gastrointestinal, etc.) in less than 1% of the patients. 
Ototoxicity, nephrotoxicity, neurotoxicity, anemia, 
granulocytopenia, thrombocytopenia, fever, rash, 
exfoliative dermatitis, itching, urticaria, diarrhea, 
headache, lethargy, pain at the injection site, mental 
confusion, disorientation. 
Hemstreet & Diprio, 
2008; Khan et al., 2011. 
Inhibitors of TNF-α 
Infliximab 
Adalimubab 
Etanercept 
Certolizumab 
Acute infusion reactions, serum sickness, increase in 
serious infections (e.g. sepsis, pneumonia, 
tuberculosis), worsening of existing heart failure 
and even death.  
Tursi et al., 2010; Talley 
et al. 2011.  
Table 2. Adverse effects of drugs most commonly used for the treatment of colitis 
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2. Colon as a target for drug and probiotic cell delivery in colitis; biological 
and (patho)physiological factors  
The principal goals of colon-specific delivery after oral administration are to prevent 
biodegradation of drugs and maintain viability of the probiotic cells in the stomach and 
small intestine where acid- or enzyme-labile drugs and cells are degraded, to avoid 
absorption of drugs in the upper intestine and accordingly, to release the drugs or to 
provide colonization of the cells in the lower intestine. Motility of the GIT, high surface area 
of the small intestine, pH of the intestinal fluids, bacterial flora, they all can affect and to a 
certain instance be an obstacle for efficacious colon targeted and controlled drug/cell 
delivery after oral administration. The segmental contractions of the colon increase the 
contact with the mucosa, which in turns promotes the design of mucoadhesive drug 
delivery systems for colon targeted and prolonged drug/cell release. Colonic transit time of 
a single-unit delivery systems varies significantly within a day; app. 6 hours are needed for 
the form to reach the transverse colon in the morning at fasting state, while in the evening, 
the colonic transfer is slower and app. 11 hours are needed for the dosage form to reach the 
transverse colon. The transit time from the stomach to the large intestine is 2-4 h and from 
the small intestine to the anus 6-48 h. This transit time may be altered by many factors, such 
as age, sex, dietary and disease factors (Washington et al., 2001).  
The pH in the GIT ranges from 1.3-1.7 in the resting human stomach to 6.4 in duodenum, 
and then drops to the range of 5.0-6.5. In the colon, pH ranges from 6.4±06 in the ascending 
part to 6.6±08 in the transverse colon and 7.0±0.7 in the descending part (Washington et al., 
2001). The literature data related to the colonic pH values in the state of colitis are 
controversial, pointing to increase, decrease or no change of pH at all (Nugent et al., 2001). 
Unpredictable alteration of the pH profile may significantly affect the viability of the cells 
and local bioavailability of the drugs by changing their chemical stability and degree of 
ionization i.e. absorption. This effect is particularly emphasized when delivery systems 
composed of pH sensitive polymers as drug or cell carriers for colon targeted and controlled 
release are used.  
The total metabolic activity of the colonic wall is much lower than the one in the upper gut, 
so, the enzymatic degradation of drugs and cells is insignificant. However, the low redox 
potential favors the growth of low number of fungi and around 1012 viable bacteria/g of 
large bowel content in human. App. 400-500 bacterial are present, dominantly obligate 
anaerobic species which produce enzymes for lot of metabolic reactions that affect the drug 
and cell release from their delivery systems. This effect is especially emphasized when 
biodegradable polymers/systems are used. The predominant anaerobic species in the colon 
are Bacteroides, Bifidobacterium, Clostridium, Euboacterium, Fusobacterium, Peptococcus, 
Peptostreptococcus, whilst facultative aerobes are represented by E. coli, Klebsiella, 
Streptococcus, Staphylococcus, Bacillus and Lactobacillus. The enzymes they produce are ┚-
glucuronidase, ┚-galactosidase, nitroreductase, azoreductase, etc. Number of mucosal 
bacteria increases progressively in the state of inflammation, with concentrations relatively 
higher in patients with active disease (Prakash & Urbanska, 2008).  
The goblet cells, which together with absorptive and endocrine cells make up the colonic 
epithelial layer, are responsible for the production of mucus. In the inflamed state, patients 
manifest reduced thickness of the colonic mucus layer due to the reduced number of the 
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goblet cells. The mucus layer is nearly free of bacteria in the mid to distal murine colon, but 
this is not true for the mucosa-adjacent and luminal regions of the caecum and proximal 
colon. Microorganisms co-aggregate and form biofilms that adhere to the epithelial surface 
(Strugala et al., 2008). Fast mucus turnover in colitic patients followed by increased activity 
of the bacterial enzymes and high concentrations of positively charged amino acids in the 
peptide core of the mucins may affect the affinity of charged drugs and cells and/or drug 
and cell delivery systems towards mucosa. Electrostatic interactions that occur may 
intensify adhesion to the inflamed mucosa and prolong the residence time of the delivery 
system or drug or cell in the colon. This effect is especially emphasized when bioadhesive 
polymers as drugs and cell carriers are used. Providing intimate contact with the mucosa, 
systems composed of bioadhesive polymers become resistant to GI motility, whilst the drug 
or cell release rate is controlled by the polymers’ hydration, erosion and biodegradation.  
It is well known that adaptive immune system relays on the lymphocytes, which are 
organized in Peyer’s patches and isolated follicles. M-cells, a constitutional part of the 
follicle-associated epithelium, are responsible for sampling of particulate materials, 
including microbial cells. In inflamed mucosa, M cells get damaged and increased, which 
can significantly affect the selective retention of the small particles in the colon. This is 
especially significant when multi-particulate dosage forms, with different size distribution, 
as drug or cell carriers are administered (Washington et al., 2001).  
Considering above mentioned, a design and development of advanced drug and cell carrier 
systems that react exclusively to the conditions in the colon and deliver their content with a 
controlled rate is of paramount importance. These systems can be optimized by using pH- 
sensitive and biodegradable polymers that provide selective adhesivity to the colonic 
mucosa. Delivery to the proximal colon may be achieved only when these systems remain 
intact for app. first 5 hours after administration and release their content within 10-24 hours.  
3. Drug and cell delivery systems in colitis; strategies for targeted and 
controlled delivery 
Advanced systems for colon-targeted and controlled drug and cell delivery in colitis are 
designed to modify drug and cell release and induce desired local effect by releasing the 
drug/cells in high concentrations close to the disease area, thereby minimizing systemic 
side effects. With these modified release dosage forms, not only therapeutic, but also safety 
and convenience objectives are accomplished, which are not typical for the conventional 
dosage forms. In conventional (non-parenteral) delivery, when using so called immediate–
release dosage forms, blood concentrations of the drug rise after drug administration, than 
peak and decline. In such dosage forms, only the dose and dosing interval can vary and, for 
each drug, there exists a therapeutic window of plasma concentration below which the 
therapeutic effect is insufficient and above which toxic side effects occur.  
An ideal form of colon drug delivery is a sustained or controlled form of drug release, which 
provides extended release, keeps plasma concentrations constant within the therapeutic 
window, and in this way, reduces dosage frequency at least two fold in comparison with the 
immediate release dosage form. The goal of the controlled release dosage forms is usually 
accomplished by attempting to obtain zero-order drug release. Drug carriers generally do 
not achieve this type of release considering lot of difficulties in dosage form design and 
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production, but providing drug release in a slow first-order fashion results also in 
prolonged therapeutic effect. Delayed release dosage forms (e.g., enteric coated forms) are 
designed to release the drug at a time different than immediately after administration. The 
delay may be controlled by the influence of the environmental factors (e.g., GI pH, bacteria, 
temperature, pressure, etc) and time-controlled, such as in pulsatile release systems. The 
pressure controlled colon delivery utilizes the increase in pressure of the luminal contents in 
the colon due to the reabsorption of water. pH-sensitive delivery utilizes solubility of the 
drug carrier in the luminal content of the colon, while in bacteria dependant delivery, 
colonic bacteria are utilized to degrade the drug/cell carrier. In pulsatile release systems, a 
complete and rapid release follows lag time. They are generally designed according to the 
circadian rhythm of the body with an aim to deliver the active ingredient at the right site of 
action, at the right time and in the right amount. In the colon delivery, this approach is 
based on principle of delaying the time of release of about 5 hours.  
3.1 Conventional topical dosage forms  
Rectal installation is an established approach for the treatment of the disease distally located 
up to the sigmoid descending junction. It has the advantage of shortest distance to the colon; 
however, it is inconvenient and followed by difficulties in reaching the proximal colon 
(Table 3). In general, suppositories, foams and liquid enemas as dosage forms are used. The 
selection of the type of the rectal preparation depends on the proximal extent of 
inflammation, ease of insertion and patient preference. Suppositories or foams reach about 
15 to 20 cm, while liquid enemas distribute to about 30 to 60 cm (to the splenic flexure) and 
sometimes as far as the ascending colon (Washington et al., 2001). So, suppositories are 
generally indicated for the disease located to the rectosigmoid junction, whereas foam 
enemas are usually distributed to the proximal sigmoid colon. In most patients, liquid 
enemas can deliver the drug as proximal as the splenic flexure. Foam and liquid enemas 
appear to be equally effective in treating patients with proximal UC, however, foam enemas 
are preferred because their administration is more easier and retention is more comfortable. 
Suppositories are usually better tolerated than enemas (Travis et al., 2008). Instilled volume 
and the viscosity of the enema are the most important variables defining proximal 
spreading of drugs. As large is the volume and the viscosity, more consistent is the proximal 
coating.  
Rectal preparations of 5-ASA and corticosteroids are used as preferred treatment for mildly 
to moderately active left-sided or distal UC. The mechanism of action of 5-ASA is very 
complex and includes inhibition of cyclooxigenase and lypooxigenase, blocked production 
of leukotrienes and prostaglandins, inhibition of adenosine-induced secretion and bacterial 
peptide-induced neutrophil chemotaxis, scavenging of reactive oxygen metabolites and 
inhibition of activation of nuclear regulatory factor kappa B (Hemstreet & Diprio, 2008). 
Meta-analyses of clinical trials point to superior effect of rectal 5-ASA in comparison with 
placebo and conventional rectal corticosteroids in inducing remission of distal UC, which 
indicates the use of rectal steroids as reserves for 5-ASA when treatment with amino-
salicylates failures or intolerance occurs (Marshall et al., 2010). When efficacy and 
convenience of administration of different rectal 5-ASA formulations were compared, no 
significant difference in efficacy was observed, while foams and gels were evaluated as the 
most convenient, producing less abdominal bloating. Considering adverse effects, reduced 
rate in respect to oral administration was reported (Sonu, 2010).  
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In colitis, corticosteroids are believed to modulate the immune response and inhibit 
production of cytokines and mediators being the benchmark therapy for moderate to severe 
UC and CD. Because of their adverse effects (Table 1), they should be used only in short 
term to induce remission in active UC, stopped once remission has been achieved and 
gradually discontinued. As selection criteria for rectal administration, corticosteroids with 
high efficacy and low systemic concentration are preferred, in order first-pass effect and 
adrenal suppression to be minimized and other adverse effects as well (Hanauer, 2002). 
Rectal formulations of prednisolone-metasulfobenzoate, budesonide, fluticasone, tixocortol 
pivalate and beclomethasone dipropionate are commercialized due to their lower 
interference with the adrenocortical function in comparison with hydrocortisone acetate and 
betamethasone (Gionchetti et al., 2004; Hanauer, 2002). Budesonide has been the 
corticosteroid of choice marketed as foams, liquid enemas and suppositories. It manifested 
efficacy in the induction and short-term maintenance of CD and induction of remission in 
collagenous and microscopic colitis (O’Donell, 2010). Comparison of the efficacy, 
tolerability, safety and patient’s preference of budesonide foam vs. enema pointed to no 
significant difference in efficacy and safety and confirmed better tolerability and easier 
application of the foam formulations (Gross et al., 2006).       
The use of immunosuppressant drugs is effective for long-term treatment of UC and CD. 
These agents are generally reserved for patients refractive to steroids and they are 
associated with serious adverse effects, which are potentiated with their relatively long-term 
use (Table 1). Rectal foams of azathioprine have been patented (Sandborn, 2002) and in one 
study in which healthy human subjects were included, pharmacokinetics of azathioprine 
after intravenous, oral, oral delayed release and rectal foam was compared. Rectal foams 
considerably reduced systemic 6-mercaptopurine bioavailability indicating the possibility 
for limited toxicity by local delivery of high doses of azathioprine (Van Os et al., 1996).  
3.2 Advanced drug and cell delivery systems  
Oral route is more convenient in the treatment of colitis. However, it is the longest one and 
associated by lot of obstacles for drug and cell stability and achieving high concentrations in 
the colon. Various strategies have been used to overcome these obstacles and to avoid high 
systemic bioavailability. These approaches utilize either formulation-specific or (pro)drug-
specific design, while drug/cell targeting and modified release can be achieved by one or 
more of the well-established mechanisms: pH-sensitive, time-dependent, pressure-
dependent and bacteria-dependent delivery (Table 3).  
 
Principle Advantages Disadvantages 
Conventional, topical delivery systems 
Deliver drugs by rectal 
instillation of liquid 
enemas, foams and 
suppositories 
Deliver therapeutic drug 
concentrations to the distal 
regions of the colon 
Limited systemic toxicity  
Drug is protected from 
digestion 
 
Difficulties in reaching the 
proximal colon  
Inconvenient administration 
and local irritation (e.g., 
leakage, problems with 
retention, burning sensation 
and bloating) 
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Principle Advantages Disadvantages 
Less compliance than optimal  
Not suitable when high doses 
are required 
Advanced delivery  
pH–responsive delivery systems 
Release active 
ingredient in response 
to the change in pH 
throughout the GIT 
utilizing enteric 
polymers with high 
pH threshold 
Provide uniform and prolonged 
release of the active ingredient 
throughout the intestinal region 
specifically at the diseased site 
Maintain physical and chemical 
integrity of the drugs in the GIT
Preserve cell viability above 
therapeutic value during the 
passage through the stomach 
Possibility for premature 
release of the active ingredient 
in the upper GIT and loss of 
therapeutic efficacy (e.g., 
rupture of the coating in the 
stomach, etc.)  
Failure of the enteric coating to 
dissolve at the desired site of 
action (e.g., formulation error, 
reduced colonic pH due to the 
presence of SCFAs, residue of 
bile acids, CO2, etc.)   
Uncertainty of the location of 
the active ingredient release due 
to the variability in gut pH in 
colitis (e.g., reduced pH in UC, 
unknown pH in CD, etc.)   
Bacteria-triggered delivery systems 
Release active 
ingredient in response 
to the specific 
enzymatic activity of 
the microflora present 
in the colon by 
biodegradation of the 
drug/cell carrier 
Precise and direct effect at the 
diseased site of the colon 
(colon- targeted delivery) 
Maintain stability of drugs/ 
viability of cells in the upper 
GIT 
Control drug/cell release 
Lower the required dose and 
frequency of administration 
Have minimal effect/lower 
toxicity on the rest of the body 
Flexibility in design (e.g., 
prodrug design, CODESTM, 
TARGIT®, COLALTM, etc.)  
Risk of producing harmful 
substance as a product of carrier 
degradation (e.g. azo-polymer-
based formulations)  
Difficulties in attaining desired 
rate of drug/cell release (e.g., 
rapid swelling in the upper GIT, 
fast disintegration or excessive 
slow enzymatic degradation of 
the delivery system)  
Inconsistency in drug/cell 
release due to the factors that 
might affect degradation of the 
delivery system (e.g. dietary 
fermentation pre-cursors, type 
of food consumed, co-
administration of chemo-
therapeutic agents, etc.) 
In a case of prodrug, new 
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Principle Advantages Disadvantages 
chemical entity needs 
additional evaluation before 
being used as a carrier 
Time-dependent delivery systems 
Release active 
ingredient after a 
predetermined lag 
time (5-6 hours) 
utilizing enteric 
coating to withstand 
the variations in gastric 
emptying time and pH
Deliver drug at preselected time 
or pre-selected site of the GIT 
Delay or sustain drug release 
Maintain physical and chemical 
integrity of the drug in the 
stomach 
Lower the required dose and 
frequency of administration 
Reduce side-effects 
Integrate pH-sensitive and 
time-release functions into a 
single dosage form  
Time-specific delivery cannot 
be accurately predicted due to 
the inter- and intra-individual 
variations in gastric emptying 
time, peristalsis or contraction 
in the stomach and type and 
amount of food consumed  
Delivery can be affected by the 
symptoms of colitis (e.g., 
accelerated transit time through 
different regions of colon due to 
diarrhea, etc.) 
Osmotic-controlled delivery systems 
Release active 
ingredient utilizing 
osmotic pressure with 
a 3-4 hour post gastric 
delay 
Release drug with pre-
determined zero order rate  
Target drug locally to the colon 
Deliver drug independently of 
the physiological factors in the 
GIT 
Suitable for delivery of drugs 
with moderate water solubility 
Versatile designs deliver drug 
as short as 4 hours or provide 
constant release for up to 24 h  
Reduce side-effects 
Lower the required dose and 
frequency of administration 
Delivery can be, to a certain 
degree, affected by 
administered food  
Delivery varies with the gastric 
motility 
Irritation or ulcer may occur 
due to release of saturated 
solution of drug 
More expensive treatment 
(because of multiple 
formulation steps and necessity 
of using special equipment for 
making an orifice in the system)  
Pressure-controlled delivery systems 
Release active 
ingredient in response 
to the increased 
luminal pressure 
caused by the strong 
peristaltic waves in the 
colon 
Colon-specific delivery 
Drug release mechanism is 
independent of pH 
Reduce side-effects 
Lower the required dose and 
frequency of administration 
Limited understanding of the 
raised pressure phase in 
subjects with colitis  
Unpredictable delivery in the 
fed state because of the 
contractions in the stomach that 
may disintegrate the system in 
the stomach 
Table 3. Characteristics of various approaches for drug and cell delivery in colitis 
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3.2.1 pH-dependent systems   
Colonic formulations are very similar to conventional enteric-coated formulations, but 
consisted of enteric polymers with ability to withstand an environment ranging from low to 
neutral pH and stay intact for minimum 5 hours. In order to prevent premature drug release 
in the upper intestine, a combination of polymers with different solubility properties and 
water permeability/hydration rate and/or higher coating levels of enteric polymers are 
applied, thereby taking care coats not to rupture. The amount of coating depends on the 
solubility characteristics of both, the drug and the polymer(s), desired release profile and 
type of the final dosage form. Most commonly used coating polymers are derivatives of 
acrylic acid, methacrylic acid copolymers, known as Eudragit®S, Eudragit®L and 
Eudragit®S, copolymers of methacrylic acid and methyl methacrylate, Eudragit®L-100 and 
Eudragit®S-100, Eudragit FS, Eudragit P4135 F, and derivatives of cellulose in a form of 
salts, such as hydroxypropylmethyl-cellulose phthalate (HPMCP 50 and 55), cellulose 
acetate phthalate (CAP), etc., generally, with threshold pH above 4.8 to 7.0. In respect to 
formulation, coated dosage forms may be either single-unit or multi-particulate systems 
formulated as a single- or multi-layer product. The coating can be applied to a wide variety 
of solid core formulations such as (mini)tablets, capsules, pellets, granules, micro- and nano-
particles. Most of them can be further filled into gelatin capsules or compressed as tablets, 
which can be additionally coated with the same or different suitable enteric polymer. The 
multi-particulate forms are less affected by the variations in the GIT, have larger surface, 
greater potential for homogenous spreading and reproducible drug release in the inflamed 
sites of the colon (Chourasia & Jain, 2003; Singh, 2007).  
5-ASA tablets coated with Eudragit®L-100 are commercially available as ClaversalTM, 
SalofalakTM, Mesasal®, Calitofalk® and Rowasa®, while sulfasalazine tablets coated with 
Eudragit® L-100-55 and CAP as Colo-pleon® and Azulfidine®, accordingly. They can 
effectively deliver 5-ASA to the terminal ileum and proximal colon in patients with IBD, 
with a delayed release which is achieved by a relatively thick coating. Clinical studies 
indentified a mean disintegration time of 3.2 h after gastric emptying and possibility the 
drug release to start at pH 6.6. In order 5-ASA release to be delayed and release to start at 
pH above 7.0, Eudragit®S-100 was used and the prepared delayed-release tablets were 
marketed as Asacol® (Schroeder et al., 1987). In January 2007, first 5-ASA formulation for 
once-a-day dosing was approved (Lialda™, Mezavant™). It uses a patented multi-matrix 
system, whereby the 5-ASA is incorporated into microparticles of a lipophilic matrix 
dispersed within a hydrophilic matrix. This is coated by a gastroresistant polymer which 
breaks down at pH of 7.0, allowing controlled release and delayed degradation of the 5-ASA 
in the colon. Multi-particulate forms of 5-ASA pellets coated with a combination of different 
Eudragits® (Eudragit® FS 30D, Eudragit® L-100, Eudragit® S-100) and Eudragits® with 
derivatives of cellulose (e.g. EC, microcrystalline cellulose, HPMC) were also prepared to 
achieve site specific release close to the ileocaecal valve. Rapid release at pH above 7.5 was 
observed, between 6.8 and 7.2 drug release was found to be zero order, while below 6.5 no 
release occurred (Cheng et al., 2004; Di Pretoro et al., 2010). Makham & Vakhshouri (2010) 
prepared and characterized methacrylic acid/perlite composites loaded with 5-ASA. In pH 
7.4, with completed ionization, hydrolysis rate of the polymer was increased resulting in 
significant drug release.   
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For budesonide, similar pH-based systems, generally multi-particulate in a form of coated 
pellets or granules filled in gelatin capsule, are also commercially available (Budenofalk® 
and Entocort®EC) and patented (Beckert et al., 2005) In Budenofalk®, colon targeting and 
delayed release is accomplished by using ammonio methacrylate copolymer (Eudragit®RL), 
ammonio methacrylate copolymer (Eudragit®RS) and Eudragit®L-100 and Eudragit®S-100 
for coating of granules with budesonide. In Entocort®EC, coating of the granules dissolves at 
pH>5.5 when they reach the duodenum. Thereafter, a matrix of EC with budesonide 
controls the release of the drug in a time-dependent manner. Budesonide was also efficiently 
entrapped in a micro-particulate system consisted of drug loaded acetate butyrate 
microspheres coated by Eudragit®S. No drug was released below pH 7 (Rodriguez et al., 
1998). Similar results were obtained when budesonide-layered pellets were coated with an 
inner layer of a combination of Eudragit®RL PO and RS PO and an outer layer of Eudragit 
FS (Patel et al., 2010). Also, novel pH-sensitive budesonide loaded nanospheres designed for 
colon-specific delivery were prepared using polymeric mixtures of poly (lactic-co-glycolic) 
acid (PLGA) and methacrylate copolymer. They showed strongly pH-dependent drug 
release properties in acidic and neutral pH followed by a sustained release phase at pH 7.4. 
In addition, superior therapeutic effect in alleviating the conditions of induced colitis in 
animal model was observed (Makhlof et al., 2009).         
Colon targeted drug delivery systems based on methacrylic resins and/or cellulose 
derivatives has also been described for prednisolone (Thomos et al., 1985), beclomethazone 
dipropionate (Levine et al., 1987), dexamethasone (Wang et al., 2010), cyclosporine (Kim et 
al., 2001), quinolones (Van Saene, 1986), metronidazole (Obite et al., 2010) and azathioprine 
(Kotagale et al., 2010). In the study of Kotagale et al. (2010), coated tablets with azathioprine 
exploiting different polymer combinations of Eudragit-S®, Eudragit-L® and CAP were 
prepared. Desired release pattern was achieved with only 9.75% drug release in the first 5 h. 
Tacrolimus has been also formulated in colon delivery system. Namely, PLGA nanoparticles 
containing the drug were entrapped into pH sensitive microspheres, showing strongly pH-
sensitive release kinetics of both nanoparticles and the drug (Lamprecht et al., 2005). 
3.2.2 Bacteria-dependent systems  
Microbially controlled delivery is the most utilized and probably the most site-specific 
approach for colon targeting of drugs and cells because it relays on drug/cell carriers that 
are recalcitrant to the conditions of the stomach and upper intestine. When reaching the 
colon, these materials undergo degradation by enzyme or break down of the polymer back-
bone, which leads to reduction in their molecular weight, loss of mechanical strength and 
subsequent drug/cell release with a rate that correlates with the biodegradation rate. For 
this type of drug/cell delivery, synthetic and natural polymers are used utilizing prodrug or 
multi-particulate approach. Multi-particulate approach has been utilized for oral delivery of 
sulfasalazine and betamethasone, based on microparticles of different synthetic 
biodegradable (co)polymers i.e. poly(epsilon-caprolactone), polylactic acid and PLGA 
(Lamprecht et al., 2000). However, the most of the multi-particulate systems, especially 
those carrying probiotic cells, utilize natural, generally regarded as safe (GRAS) 
polysaccharide polymers. Their fermentation by the bacterial enzymes results in formation 
of volatile SCFAs, such as lactic, acetic, propionic and butyric acids. Knowing that their 
deficiency causes UC, one can postulate that administering probiotics alone or with 
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prebiotics, with complex carbohydrate structure, or embedded in polysaccharide carriers 
could be significantly beneficial in the treatment of colitis. 
i. Polysaccharide-based systems 
Lot of advantages promote the use of polysaccharides as drug carries for colon-targeted and 
controlled delivery, such as wide availability and inexpensiveness, variety of structures, 
simplicity for (bio)chemical modification, stability, safety, non-toxicity, mucoadhesivity, pH 
sensitive solubility and gel-forming properties. Of polysaccharides, guar gum, inulin, 
chitosan, chondroitin sulphate, alginates and dextran are the most used (Kumar et al., 2009). 
However, these materials are with certain limitations. Their hydrophilic nature makes them 
either soluble or prone to swelling in an aqueous environment and hence unsuitable as drug 
or cell carriers. So, when they are used alone, large quantities are needed to target the colon 
and control the drug release. To overcome these problems, cross-linking of soluble 
polysaccharides with poly- or di-valent cations or anions, accordingly, to form insoluble 
salts, or coating with mucoadhesive and oppositely charged pH sensitive polymers is 
applied. In this way, combined mechanisms for colon targeting, controlling drug release and 
increasing mean residence time in the colon are utilized.  
For 5-ASA delivery, colon specificity has been achieved using a system based on amylose 
(COLALTM), which is susceptible to digestion by amylase-producing bacteria present in the 
colon. To control the swelling in the aqueous media and in that way, 5-ASA release rate, 
pellets were coated with amylose coating solution prepared along with the hydrophobic 
polymers Ethocel®, Eudragit RS/RL 30D and Aquacoat ECD30 (Milojevic et al., 1996). In 
addition, successful colon delivery of prednisolone metasulfobenzoate with COLALTM 
system in patients with active UC was reported (Thompson et al., 2002). Similarly, 
dispersion of pectin in EC was used as the film former for coating of 5-ASA pellet cores. 
Negligible drug release during first 5 h in the simulated gastric and small intestinal 
conditions was observed. Osmotically driven release and formation of channels in the film 
caused by dissolution of pectin and activated by the presence of rat caecal contents was 
proposed as a drug release mechanism (Wei et al., 2008). Similar results have been obtained 
when a tablet systems based on swelling matrix core containing pectin, HPMC, 
microcrystalline cellulose and 5-ASA was developed in which drug release rate was 
controlled by pectinases (Talukder & Fasihi, 2008). The systems were designed based on GI 
time concept, assuming colon arrival time of 6 h.   
 
Fig. 1. Confocal laser scanning microscopy of 5-ASA loaded chitosan-Ca-alginate 
microparticles showing FITC-labeled chitosan (green) coating RBITC-labeled Ca-alginate 
matrix (red) (Mladenovska et al., 2007a,b). 
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Chitosan has also been extensively exploited as a 5-ASA carrier. For example, specific 
release of 5-ASA in the colon was achieved with chitosan capsules coated with HPMCP as 
enteric solvent material; efficacy in induced colitis in rats was confirmed as well as 
superiority in respect to the commercial 5-ASA products (Tozaki et al., 2002). 5-ASA loaded 
chitosan microspheres showing colon specific and controlled release were also prepared by 
Zambito & Di Colo (2003). In our studies (Mladenovska et al., 2007a,b), chitosan-Ca-alginate 
microparticles (Fig. 1) for colon-specific delivery and controlled release of 5-ASA after oral 
administration were prepared. In vitro drug release studies carried out in simulated in vivo 
conditions and biodistribution studies performed in colitic rats confirmed the potential of 
the particles to release the drug in the colon, with low systemic bioavailability. Similarly, 
beads containing 5-ASA, Eudragit FS 30D, Eudragit S-100 and chitosan were prepared (Iruin 
et al., 2005).  
Corticosteroids were also incorporated in polysaccharide-based colon delivery systems. 
Multi-particulate system showing specific biodegradability and pH-dependent 
triamcinolone release were prepared based on chitosan, amidated pectin, HPMCP and CAP. 
Only 1% of drug was released in the acidic media after 2h (Oliveira et al., 2010). Novel colon 
delivery system COLAL-PRED has been developed by Alizyme for the treatment of UC as a 
combination of Alizyme’s properitary colonic drug delivery system COLAL and 
prednisolone sodium metasulfobenzoate. The product has a coating that breaks down only 
in the colon by locally present bacteria, thus increasing local drug delivery without 
significant systemic side effects (Rangasamu, 2010). Budesonide was microencapsulated 
with dextran and the formulation was in vitro/in vivo characterized in induced colitis in rats. 
Colon targeting was confirmed and the macroscopic damage and total colitis scores were 
significantly reduced in comparison with the control group receiving 5-ASA and 
budesonide suspension (Varshosaz et al., 2011a). When budesonide release from directly 
compressed matrix tablets prepared of different molecular weights of dextran was 
evaluated, app. 10% of the drug was released in acidic pH and pH 7.4, while a very drastic 
increase was observed after exposure to pH 6.8 containing rat caecal contents (Ahmadi et al., 
2011). Budesonide loaded chitosan-Ca-alginate microparticles coated with Eudragit S-100 
were also prepared showing sustained release in pH 2.0 and 6.8 and efficient release in pH 
7.4 controlled by the erosion and biodegradation rate of the polymer matrix. Clinical and 
histological evaluation in rat model of colitis showed that colitis severity was significantly 
suppressed (Crcarevska et al., 2009).  
A multi-particulate system combining pH-sensitive property and specific biodegradability 
for colon-targeted delivery of metronidazole has been also investigated. The system was 
prepared by coating cross-linked chitosan microspheres with Eudragit L-100 and S-100. No 
release was observed at acidic pH, but in the presence of rat caecal contents, significant 
release was observed, indicating the susceptibility of chitosan matrix to colonic enzymes 
(Chourasia & Jain, 2004). Pectin microspheres were also prepared and coated with Eudragit® 
S-100 showing continuous release of metronidazole at colonic pH in the presence of rat 
caecal contents (Vaidya et al., 2009). In the studies of Nasra et al. (2007), pectin as a carrier of 
metronidazole was combined with chitosan in a form of coated tablets with ability to 
prevent premature drug release.  
Azathioprine loaded Ca-gellan beads coated with Eudragit®S-100 were also prepared. The 
results suggest that gellan gum undergoes significant degradation in the presence of 
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galactomannanase, which in turn facilitates the drug release from beads in the simulated 
colonic fluid (pH 7.4) in a controlled manner (Singh et al., 2004). In the work of Chaurasie et 
al. (2008), Ca-pectinate microspheres were prepared to deliver methotrexate in the colon. In 
vitro drug release studies in simulated gastric and intestinal fluids showed that app. 8% of 
the drug was released in 5 hours, whereas most of the loaded drug was released in 
simulated colonic fluid containing pectinase.  
Polysaccharides have been also investigated as carriers for protection of the probiotics. 
Entrapment of cells in a gel matrix of alginates, chitosan, gellan, k-carageenan and starch or 
mixture of polysaccharide and protein is the most utilized approach. Cells are either 
compressed into a pellet, which is then encapsulated with the coating material by further 
compression, or encapsulated in an inner core surrounded by a semi-permeable, spherical, 
thin and strong membrane to form microcapsules or immobilized within or throughout a 
polymer matrix to form microspheres which can be subsequently filled into gelatin capsule. 
The coating of the microparticles, with a diameter from few microns to 1 mm, is designed to 
withstand acidic conditions and open in the lower intestine to release the cells by many 
different mechanisms, including fracture by heat, solvation, diffusion, pressure, erosion and 
biodegradation. The lower intestine provides right conditions for probiotic to survive, 
multiply and exert health beneficiary effects. With such a protection from acidity, molecular 
oxygen, hydrogen peroxide, digestive enzymes, bacteriophages and SCFAs, the viability of 
the probiotic after oral administration is significantly improved and targeted and controlled 
release achieved (Rokka & Rantamaki, 2010).  
Literature data point to abundance researches related to microencapsulation of probiotics 
alone or with prebiotics in coated and non-coated alginate microparticles. As prebiotics, 
usually FOS or isomaltooligosaccharides are used, while as coating materials, other 
polysaccharides or proteins. When probiotic cells were compressed into pellets and 
encapsulated within alginate as the coating material, significant improvement in survival 
(104-105-fold) was observed after exposure to acidic pH. In vitro tests pointed to a cell 
release near the end of the ileum and beginning of the colon with a mechanism involving 
erosion of the alginate gel layer (Eng Seng & Zhang, 2005). Many other formulations of 
encapsulating materials for probiotic microparticles were optimized; all of them showed 
improved tolerance to gastric conditions and high survival of the probiotic in colonic 
conditions. Of probiotics, strains of L. acidophilus, L. casei, B. bifidum and B. longum, proved to 
show health effects in colitis, are among the most studied. For example, L. casei NCDC-298 
loaded Ca-alginate microparticles showed better survival of the probiotic at low pH and 
high bile salt concentration. In colonic pH solution, the release of cells was increased, with a 
count above therapeutic minimum of 107–109 cfu g-1 (Mandal et al., 2006). Similarly, 
encapsulated L. acidophilus ATCC 43121 in Ca-alginate microparticles exhibited a 
significantly higher resistance to artificial intestinal juice than non-encapsulated samples 
(Kim et al., 2008). The beads made with alginate-pectin blends provided a significant better 
protection to the entrapped L. casei under all conditions tested (Sandovall-Castilla et al., 
2010). Strains of L. acidophilus and L. casei were encapsulated into uncoated Ca-alginate 
beads and the same beads were coated with three types of material, chitosan, Na-alginate 
and poly-L-lysine in combination with alginate. Chitosan-coated alginate beads provided 
the best protection for the lactobacillus strains in simulated GI conditions (Krasaekoopt et 
al., 2004). Also, chitosan coated microspheres were produced to encapsulate L. gasseri and B. 
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bifidum, separately with the prebiotic quercetin, with an aim to keep them intact during 
exposure to the harsh conditions of the GIT. Resistance to simulated gastric conditions 
during 2 h and bile salt solution for 2 h was observed (Chavarri et al., 2010).  
In our study, in which the probiotic L. casei was microencapsulated with FOS in chitosan-Ca-
alginate beads, the optimal formulation of synbiotic microparticles was stable during 
exposure to simulated gastric and intestinal juices and release of viable cells above the 
therapeutic value in the simulated colonic pH was observed (Fig. 2) (Petreska et al., 2010, 
2011). Similar results were obtained when L. casei was entrapped in whey protein-Ca-
alginate microparticles (Smilkov et al., 2011a,b). The same combination of whey protein and 
alginate was used for microencapsulation of strains of L. plantarium; only bacteria in the 
coated beads survived in the simulated gastric and intestinal fluid (Gbassi et al., 2009). 
Other protein and polysaccharides mixtures were also used to microencapsulate probiotics. 
For e.g, alginate-coated gelatin microspheres were prepared to encapsulate strain of B. 
adolescentis; the alginate core prevented pepsin-induced degradation of the gelatin 
microspheres and thus, cell release in simulated gastric juice for 2 h (Annan et al., 2008). 
 
 
Fig. 2. Microstructure of (a) whole and (b) fractured L. casei loaded chitosan-Ca-alginate 
microparticles (left) and viability of non-encapsulated and encapsulated L. casei in simulated 
gastric conditions (0.08 M HCl; 0.2% NaCl; pH 1.5), bile salts solution (0.05 M KH2PO4; pH 
6.8 with 1% bile salts) and colonic pH (0.1 M KH2PO4; pH 7.4) (right). The inner part of the 
particles is built of a mesh-like alginate network through which the bacteria groups are 
distributed and sequestered in voids. 
ii. CODESTM delivery system 
CODESTM is a specific polysaccharide based system exploiting specific biodegradability of 
the polymers by the colonic bacteria only in combination with pH-sensitive polymer coating 
(Fig. 3). It is consisted of a core tablet (consisted of drug, one or more polysaccharides and 
other necessary excipients) coated with three layers of polymers, acid-soluble polymer (e.g., 
Eudragit E®) around the core, outer layer of enteric polymer and a barrier between to 
prevent complexation of oppositely charged polymers (e.g., HPMC) (Pantel et al., 2008). The 
system remains intact in the stomach. Upon entry into the colon, the polysaccharides (e.g., 
FOS, mannitol, lactulose, etc.) dissolve and diffuse through the coating whereby they 
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become subject to enzymatic degradation to organic acids. As colonic pH starts to decrease, 
the acidic-soluble polymer begins to dissolve, which is followed by subsequent drug release. 
CODES, consisted of three components, a core containing lactulose and 5-ASA, an inner 
acid-soluble material layer and an outer layer of an enteric soluble material, was prepared 
and orally administered to fasting and fed dogs to evaluate the pharmacokinetic profiles of 
the drug. The results of the study confirmed that lactulose can act as a trigger for 5-ASA 
release in the colon (Katsuma et al., 2002). Recently, Varshosaz et al. (2011b) reported 
development of a novel budesonide pellets based on CODESTM technology. Pellet cores 
containing lactulose or manitol were coated with an acidic soluble polymer Eudragit E®100, 
HPMC and an enteric coat consisted of Eudragit® FS 30D. Absence of drug release in pH 1.2 
and 7.4 was observed, while in medium with rat caecal contents (pH 6.8), controlled release 
occurred. Promising results in decreasing colitis score in animal model were also observed. 
 
enteric coating 
(e.g., Eudragit FS 30D) 
barrier 
(e.g., HPMC) 
acid soluble polymer (e.g., 
Eudragit E® 100) 
 
PS + microflora 
 
 
 
   
   Organic acid 
 
         
            Drug 
stomach small intestine lower intestine 
Fig. 3. Schematics of the CO(lon)DE(livery)S(ystem)TM 
iii. Prodrugs   
Prodrug approach for colon targeting in colitis includes formation of a covalent linkage 
between the drug and a carrier, which upon oral administration of the drug remains intact 
in the acidic environment of the stomach and upper intestine and undergoes spontaneous or 
enzymatic transformation in the colon. This approach solves not only the problem of 
achieving high drug concentration at the diseased site, but also the problem of preserving 
chemical stability and avoiding high systemic bioavailability and thereby toxicity. There are 
three classes of prodrugs commercially available or under investigation: (i) anti-
inflammatory agents (e.g. 5-ASA, SCFAs); (ii) immunomodulators (e.g. corticosteroids, 
azathioprine); and (iii) antioxidants (e.g. glutathione, cysteine, S-adenosyl-methionine) 
(Chourasia & Jain, 2003; Oz & Ebersole, 2008).  
All available methods for covalent linking of 5-ASA molecule were used: linking via azo-
bond to another 5-ASA molecule (in olsalazine) or inert carrier 4-amino-benzoyl-┚-alanine 
(in balsalazine) or active carrier sulfapyridine (in sulfasalazine) and subsequent activation of 
the drug in the colon by the bacterial azoreductases as well as conjugation with amino acids 
or polymers as polymeric prodrug systems. Sulfasalazine releases 5-ASA specifically in the 
colon, however, a small quantity of the ingested dose is absorbed in the upper intestine 
resulting in serious adverse effects of sulfapyridine (Table 1). Olsalazine and balsalazine 
were formulated to overcome disadvantages of sulfapyridine. In the studies of Yokoe et al. 
(2003), a new prodrug was synthesized, salicylazosulfanyl acid. Azoreductases cleave it into 
5-ASA and sulfanyl acid; owing to the high hidrophylicity of the carrier and thereby low 
Drug + PS  
(e.g., lactulose, manitol, 
FOS, stachyose, maltose) 
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absorption in the GIT, adverse effects observed with sulfapyridine were avoided. The use of 
┚-cyclodextrins as 5-ASA carriers in a prodrug form was characterized by a relatively 
successful prevention of 5-ASA release in simulated gastric and intestinal medium and 
subsequent release mediated by the colonic microflora (Bonsignore, 2000). Jung et al. (1998) 
formulated stable dextrane conjugate of 5-ASA with delayed release. Lately, they focused 
their research towards conjugation of 5-ASA with amino acid derivatives where 5-
aminosalicyl-L-aspartic acid and 5-aminosalicyl-L-glutamic acid were synthesized and their 
properties as colon-specific prodrugs of 5- ASA investigated in colitic rats (Jung et al., 2001). 
The most of 5-ASA-Asp was delivered to the large intestine and about half of the 
administered dose was activated to liberate 5-ASA. Recently, an amino acid (mutual) aza- 
prodrug of 5-ASA was synthesized by coupling L-tryptophan with salicylic acid (Nagpal et 
al., 2007). In vitro kinetic studies showed negligible release of 5-ASA in acidic medium, while 
in vivo studies pointed to equal attenuation of the colitis in rats as that of sulfasalazine 
without ulcerogenicity of 5-ASA. One more attempt was made to conjugate 5-ASA for colon 
delivery. Specificity includes conjugation with bile acids (chenodeoxycholic and 
ursodeoxycholic acid) (Goto et al., 2001). In vivo studies in guinea pigs showed that with 
lower doses, higher efficacy could be achieved. Polymeric prodrugs of 5-ASA were also 
formulated in which 5-ASA was linked with polyacrylic or polyamide polymers via 
degradable ester or amide bonds (Zou et al., 2005) as well as polymeric prodrugs in which 5-
ASA was bond via azo-carrier to polyanhydride polymers and derivatives of dextrane and 
poly[(2-hydroxylethyl)aspartamine] (Cai et al., 2003). In the recent studies of Yadav & 
Mahatma (2011), acrylic type polymeric systems having degradable ester bonds linked to 
the 5-ASA were synthesized and evaluated for colon targeted drug delivery. In vitro drug 
release studies, conducted at pH 1.2, 7.4 and in rat fecal content, pointed to a burst release of 
app. 40% in the first 2 h followed by a sustained release over a period of 12 h. In general, 
most of the mentioned prodrugs and polymeric prodrugs release 5-ASA successfully in the 
colon, but the complex coupling processes and the fact that the 5-ASA content is app. 10% of 
the total mass made them inappropriate for oral administration because a very large amount 
would need to be taken orally (Chourasia & Jain, 2003).  
Corticosteroids were also subject to prodrug design. Steroid glycosides, galactosides and 
cellobiosides were designed, from which dexamethasone, prednisolone, hydrocortisone and 
fludrocortisone were released in the colon with hydrolysis mediated by ┚-D-galactosidase, 
┚-D-glucosidase, ┙-L-arabinofuranosidase, ┚-D-xylopyranosidase (Friend & Chang, 1985). In 
vivo researches involving rat stomach, proximal small intestine, distal small intestine and 
caecum pointed to the most rapidly hydrolysis in the caecal content followed by the distal 
small intestine. Conjugates of budesonide and dexamethasone and glucuronic acid and 
dextran, accordingly, were also synthesized, showing excellent efficacy in rats with induced 
UC and decreased toxicity, especially in respect to adrenal suppression (Nolen et al., 1997; 
Varshosaz et al., 2009). Also, dexamethasone 21-sulfate sodium as a colon specific prodrug 
of dexamethasone was prepared (Kim et al., 2006). The degree of prodrug hydrolysis and 
production of dexamethasone amounted to 70% of healthy rats when a prodrug was 
incubated with caecal contents collected from colitic rats. In comparison with prednisolone, 
hydrocortisone and cortisone, dexamethasone was stable against bioinactivation by the cecal 
contents. Anti-inflammatory effect and systemic side effects of prednisolone succinate/-
cyclodextrin ester conjugate were also studied in animal model of IBD (Yano et al., 2002). 
The side-effects were significantly alleviated due to the passage of the conjugate through the 
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stomach and small intestine without significant degradation or absorption. Dextran ester 
prodrugs of dexamethasone and methylprednisolone, with a succinate linking the drug and 
dextran, were also synthesized and proved their preclinical efficacy and lower toxicity (Pang 
et al., 2002). Similarly, budesonide-succinate-dextran conjugate as a prodrug of budesonide 
showed huge improvement in macroscopic and histological scores of colitis in induced 
colitis in rats (Varshosaz et al., 2010). Polymeric prodrug colon delivery system of 
dexamethasone was also prepared, with poly-(L-aspartic acid) as a carrier with superior 
efficacy and lower toxicity in respect to oral dexamethasone (Leopold & Friend, 1995).  
3.2.3 Time-dependent systems   
In ideal time-controlled colon delivery system, drug release occurs after precisely 
determined lag phase of minimum 3±1 h necessary for the system to pass the stomach and 
small intestine. In fact, the system relays on the consistent small intestine transit time, while 
for the formulation to withstand the individual variations in gastric emptying time and pH, 
usually enteric coating is used. This prevents rapid swelling and disintegration in the upper 
GIT, while in the colon, drug release rate is controlled by the mechanisms of swelling, 
osmosis or diffusion, erosion or a combination of all (Singh, 2007). In general, it is very 
difficult colon specific and controlled release in a state of colitis and diarrhea with this type 
of delivery systems to achieve because the transit through different regions of the colon is 
accelerated and unpredictable.  
Various structures and formulation designs were commercialized (Pulsincap®, Time Clock®) 
and described for this type of delivery systems, mostly adapted from the pulsatile delivery 
systems. They can be subdivided into reservoir and capsular formulations prepared in a 
form of single- or multiple-unit preparations (Iamartino et al., 1992; Takada, 1997; Ueda et 
al., 1989). Usually, in all designs, drug, one or more swellable hydrophilic excipients (e.g., 
sodium starch glycolate, CMC sodium, low substituted HPC) and water-insoluble enteric 
polymers (e.g., EC, Eudragit® RL) are present. Patent assigned to Hoffman-La Roche (Shah 
et al., 2000) contains also a plasticizer in an inner semi-permeable polymer membrane, 
which allows water influx but prevents the outward diffusion of the drug. An outer enteric-
coating, which dissolves above pH 5.5, swells during the transit of the tablet through the 
small intestine and after a consistent period of minimum 4 h transit in the small intestine, 
the swollen core burst the semi-permeable membrane and the drug is released in the colon. 
In the erodible systems, the penetration of the GI fluids through the micropores of the outer 
layer causes swelling/expansion, dissolution and/or erosion of the swelling agent(s), which 
accordingly, pushes the drug out of the system or delays the drug release for a time 
determined with the selection of the coating polymer(s). In rupturable reservoirs, a time for 
release of the drug is programmed by the disruption of a semi-permeable membrane 
consisted of insoluble polymer(s). In the device of Ritschel & Agrawal (2002), for example, 
self-destruction of the semi-permeable membrane occurs and the drug goes out of the 
system though the orifice made by a specific press-coating. Concerning the capsular 
systems, the drug release occurs after dissolution of a protective polymer cap and 
subsequent removal of a matrix plug from a drug-containing insoluble capsule body; the 
time of ejection corresponds to the lag phase. 
Time-dependent system for delivering 5-ASA to the colon was prepared in which the core 
tablet of 5-ASA was compression-coated with HPMC and then coated with Eudragit®L-100. 
www.intechopen.com
 
Drug and Cell Delivery Systems in the Treatment of Colitis 
 
149 
The results revealed that the lag time increases with the amount of HPMC (Patel et al., 2009). 
Combined time- and pH-dependent microparticulate system consisting of non-
enzymatically degrading PLGA core for delivering budesonide specifically to the distal 
ileum and colon was also developed. Eudragit®S-100 was used to form a coating on the 
surface of the microparticles. Complete retardation of drug release in an acidic pH and 
controlled release in pH 7.4 and 6.8 was observed (Krishnamachar et al., 2007). In addition, 
Yehia et al. (2009) optimized a formulation of budesonide loaded compression-coated 
tablets where as time-dependent variable, cellulose acetate butyrate was used.      
3.2.4 Osmotic-controlled systems   
In general, in osmotic drug delivery systems, the delivery of the active agent(s) is delayed or 
pulsed, driven by an osmotic gradient and it is not dependent /affected by the physiological 
variables within the GIT. After administration, the water diffuses into the core of the 
osmotic system through a semi-permeable membrane increasing the hydrostatic pressure, 
which pumps the active agent containing solution out of the core through one or more 
orifices. The drug release follows zero order kinetics and the rate is controlled by the 
diffusion rate of the water into the system (Gupta et al., 2009). 
 
Fig. 4. Osmotic pump capsule structure 
Lots of osmotic delivery systems, with membrane plug retention mechanism or with 
osmotic device in an osmotic device, have been patented, with a potential to carry the drugs 
for the treatment of different states of colitis. Therapeutic System Research Laboratory Arm 
Arbor (Michigan, USA) developed the Port system consisting of a capsule coated with a 
semi-permeable membrane. Inside the capsule is an insoluble plug consisting of osmotically 
active agent and the drug formulation (Fig. 4). Osmotic system OROS-CT was designed by 
Alza Corporation to target the active agent(s) to the colon. It is a system composed of a 
single or multiple (5-6) bi-layered osmotic units encapsulated within a hard gelatin capsule. 
Each layer, the push and drug layer, are surrounded by a semi-permeable membrane, while 
the orifice is drilled through the membrane next to the drug layer. Semi-permeable 
membrane, usually consisted of CA and cellulose acylate, is insoluble in body fluids, non-
erodible, but permeable to the passage of fluids. Each unit is surrounded by enteric coating, 
usually phthalates, keratin, formalin-treated protein, oils and anionic polymers, which do 
not dissolve, disintegrate or change their structure in the stomach. The osmogents are either 
hydrophilic polymers (e.g., HPMC, poly(hydroxyalkyl-methacrylate), poly(vinyl-
pyrrolidone), poly(vinyl alcohol), acidic carboxy-polymers or inorganic water-soluble agents 
(e.g., magnesium sulfate, sodium- and potassium chloride, sodium bicarbonate, etc.). In UC, 
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drug release begins when the drug enters the colon, with 3-4 h post gastric delay. Then, a 
constant release follows which may last up to 24 h (Gupta et al., 2009; Patel et al., 2010).  
Specifically, a new microbial-triggered colon targeted osmotic pump was developed for 
colon delivery of budesonide based on chitosan. Chitosan was used to produce osmotic 
pressure by swelling and with its degradation, in situ delivery pores were formed through 
which budesonide was released. CA along with chitosan was coated on a tablet as a semi-
permeable membrane, while as entering coat, Eudragit®L-100-55 was used (Liu et al.; 2007). 
3.2.5 Pressure-controlled systems   
The rationale behind the design of the pressure-dependent colon delivery systems lies in the 
existence of strong peristaltic waves that move intestinal content from ascending to 
transverse colon, temporarily increasing the luminal pressure within the colon. Significantly 
higher viscosity of the colonic content is a reason for much higher luminal pressure in the 
colon in comparison with the one in the small intestine. So, the delivery system is 
formulated to withstand the pressure in the upper GIT and to collapse in the lower intestine.  
So far, pressure-controlled colon delivery capsules (PCDCs) as a unique system were 
prepared by coating an inner surface of gelatin capsules with EC. By adjusting the coating 
thickness of the EC membrane, colon delivery of 5-ASA in beagle dogs was obtained. 
Namely, after administration, 5-ASA appeared into the systemic circulation after 3-5 h, 
which corresponds to the colon arrival time observed with sulfasalazine (Muraoka et al., 
1998). Avoiding side effects of sulfapyridine is a great achievement with this type of colon 
delivery system. Furthermore, 5-ASA was loaded in microcapsules prepared of EC or 
Eudragit L-100 or S-100 and filled into PCDCs, which were prepared as fast release colon 
delivery system with 5-ASA powder suspended in a suppository base. The release rate of 5-
ASA from the microcapsules was significantly prolonged as compared to 5-ASA powder 
with no significant differences in the release rates between the microcapsules. The first 
appearance time of 5-ASA into the systemic circulation after oral administration was 3 h for 
all the colon delivery preparations, while both EC microcapsules and Eudragit®S-100/RS-
100 microcapsules in PCDCs showed longer mean residence time than Eudragit®L-100/RS-
100 microcapsules, suggesting sustained release characteristics (Hu et al., 1999).  
4. Conclusion and future perspectives  
Undoubtedly, advanced colon drug delivery systems (CDDSs) offer significant advantages 
in respect to both efficacy and safety of drugs used for the treatment of colitis and 
considering probiotic cells, significantly increased survival and colonization rate. However, 
commercial products for oral administration based on the mentioned CDDSs for all the 
drugs needed for the treatment of colitis, especially for biologic drugs, are still not available. 
In this respect, multidisciplinary project was initiated by the research group from the 
University Medical Center Groningen to develop and evaluate oral formulations of 
infliximab, including formulation based on pH-responsive coating containing Eudragit®S-
100. Similarly, formulation of infliximab loaded PLGA microspheres was developed by 
Foong et al. (2010) as a prospective novel treatment of CD fistulae showing controlled 
release under zero-order kinetics of the anti-TNF-┙ antibody and biological activity against 
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TNF-┙. Also, to the present knowledge, no commercial pharmaceutical product containing 
microencapsulated probiotic cells exists. 
Of all the primary above-mentioned approaches proposed for the CDDSs none is ideal when 
separately used and colon specificity and controlled delivery is more likely to be achieved 
with systems based on mucoadhesive natural materials that are degraded by the colonic 
bacterial enzymes. Considering the complexity of the CDDSs and the difficulties in 
establishing in-vitro/in-vivo correlation by actual dissolution methods, a validated 
dissolution method for their evaluation has to be developed, which considers the 
physiological characteristics of the colon and can be used routinely in an industry. In 
addition, novel approaches developed for colon-targeting and controlled release, as even 
more specific, have to be comprehensively explored and commercialized as drug/cell 
carriers in the treatment of colitis. Extensive clinical data showing promising efficacy in 
active colonic diseases, including IBD, are now available for TARGIT Technology (West 
Pharmaceutical services) designed for targeted release into the colonic region. The 
technology is based on application of pH-sensitive coatings onto injection-moulded starch 
capsules. Also, the ENTERION capsule has recently been developed (Phacton Research, UK) 
for targeted delivery of different drug formulations into any region of the gut. The round-
ended capsule sealed by inserting a push-on cap fitted with a silicone O-ring can be loaded 
with either a liquid formulation or a particulate formulation (e.g., micro/nanoparticles, 
pellets, etc.). The bottom of the drug reservoir is the piston face which is held back against a 
compressed spring by a high tensile strength polymer filament. Once the capsule reaches the 
target location in the GIT, the drug is actively ejected by the external application of an 
oscillating magnetic field. Clinical application and converting this tool into a product-carrier 
of drugs for colitis treatment remains a big challenge. Therefore, a search for new delivery 
systems that can provide increased therapeutic benefits to the patients with colitis continues.  
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